Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Ocuphire Pharma
Ocuphire Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Ryzumvi
Phentolamine
2023-09-25
2034-2039
Necrosis
,
Extravasation of diagnostic and therapeutic materials
,
Malignant hypertension
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Phentolamine
multiple myeloma
,
plasma cell neoplasms
,
neoplasm metastasis
Alfacalcidol
fecal incontinence
Clavulanic acid
infections
,
communicable diseases
,
chronic bronchitis
,
bronchitis
,
acute disease
,
sinusitis
,
maxillary sinusitis
,
bacterial skin diseases
,
skin diseases
,
otitis media
,
otitis
,
ventilator-associated pneumonia
,
pneumonia
,
cross infection
,
community-acquired infections
,
bacterial pneumonia
,
urinary tract infections
,
pyelonephritis
,
appendicitis
,
intraabdominal infections
,
abdominal pain
,
abscess
,
peritonitis
,
abdominal abscess
,
ileus
,
intestinal perforation
,
acute abdomen
,
rupture
Lactams
pneumonia
,
chronic bronchitis
,
sinusitis
,
bronchitis
,
bacterial pneumonia
APX3330
macular edema
,
retinal diseases
,
diabetic retinopathy
Demand
acute pain
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use